Clinical Trial Update: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in relapsed/refractory gray-zone lymphoma, primary CNS lymphoma, and other extranodal diffuse large B-cell lymphomas has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma
• Gray Zone Lymphoma
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-Hodgkin Lymphoma, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-28